Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for Parkinson's disease hallucinations
2019-003962-41Phase 2Unknown
- Sponsor
- University College London
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Ondansetron with Placebo (2 arms). Primary endpoint: SAPS Hallucinations score at 12 weeks. Status: unknown.
02
Drugs
ondansetron
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-003962-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003962-41.